Efficacy and Safety of Ixekizumab Over 4 Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

Interleukin-17A is a critical cytokine involved in psoriasis pathogenesis., The efficacy of ixekizumab, an interleukin-17A monoclonal antibody, was maintained for up to 4 years without apparent increases in health risks or safety issues in moderate-to-severe psoriasis patients., Long-term ixekizumab treatment is an option for moderate-to-severe psoriasis patients.